These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 29442344

  • 1. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A, Ng WF, James K, Griffiths B, Price E, Pease C, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Gupta M, McLaren J, Cooper A, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Barone F, Fisher B, Rauz S, Richards A, Bowman S.
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [Abstract] [Full Text] [Related]

  • 2. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
    Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, Gottenberg JE, Theander E, Tzioufas A, De Vita S, Ramos-Casals M, Dörner T, Quartuccio L, Ravaud P, Mariette X, EULAR Sjögren Task Force.
    Ann Rheum Dis; 2016 Nov; 75(11):1945-1950. PubMed ID: 27150113
    [Abstract] [Full Text] [Related]

  • 3. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
    de Wolff L, Arends S, Pontarini E, Bombardieri M, Bowman SJ, Bootsma H.
    Clin Exp Rheumatol; 2021 Nov; 39 Suppl 133(6):100-106. PubMed ID: 34796851
    [Abstract] [Full Text] [Related]

  • 4. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
    Oni C, Mitchell S, James K, Ng WF, Griffiths B, Hindmarsh V, Price E, Pease CT, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Hunter J, Gupta M, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Barone F, Fisher B, Rauz S, Richards A, Bowman SJ, UK Primary Sjögren’s Syndrome Registry.
    Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
    [Abstract] [Full Text] [Related]

  • 5. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
    James K, Chipeta C, Parker A, Harding S, Cockell SJ, Gillespie CS, Hallinan J, Barone F, Bowman SJ, Ng WF, Fisher BA, UK Primary Sjögren’s Syndrome Registry.
    Rheumatology (Oxford); 2018 Jul 01; 57(7):1222-1227. PubMed ID: 29608774
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X, EULAR Sjögren's Task Force.
    Ann Rheum Dis; 2016 Feb 01; 75(2):382-9. PubMed ID: 25480887
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C.
    J Autoimmun; 2014 Jun 01; 51():51-6. PubMed ID: 24411404
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
    Lancet; 2022 Jan 08; 399(10320):161-171. PubMed ID: 34861168
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V, Colic J, Cirkovic A, Stanojlovic S, Damjanov N.
    PLoS One; 2019 Jan 08; 14(12):e0226498. PubMed ID: 31891590
    [Abstract] [Full Text] [Related]

  • 14. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
    Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng WF, UK primary Sjögren’s Syndrome Registry.
    Rheumatology (Oxford); 2015 Apr 08; 54(4):655-9. PubMed ID: 25240612
    [Abstract] [Full Text] [Related]

  • 15. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
    Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanovas A, Sopeña B, Díaz-López B, Rascón FJ, Qanneta R, Fraile G, Pérez-Alvarez R, Callejas JL, Ripoll M, Pinilla B, Akasbi M, Fonseca E, Canora J, Nadal ME, de la Red G, Fernández-Regal I, Jiménez-Heredia I, Bosch JA, Ayala MD, Morera-Morales L, Maure B, Mera A, Ramentol M, Retamozo S, Kostov B, SS Study Group, Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI).
    Rheumatology (Oxford); 2014 Feb 08; 53(2):321-31. PubMed ID: 24162151
    [Abstract] [Full Text] [Related]

  • 16. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients.
    Retamozo S, Acar-Denizli N, Rasmussen A, Horváth IF, Baldini C, Priori R, Sandhya P, Hernandez-Molina G, Armagan B, Praprotnik S, Kvarnstrom M, Gerli R, Sebastian A, Solans R, Rischmueller M, Pasoto SG, Valim V, Nordmark G, Kruize A, Nakamura H, Hofauer B, Giacomelli R, Fernandes Moça Trevisani V, Devauchelle-Pensec V, Atzeni F, Gheita TA, Consani-Fernández S, Szántó A, Sivils K, Gattamelata A, Danda D, Kilic L, Bartoloni E, Bombardieri S, Sánchez-Guerrero J, Wahren-Herlenius M, Mariette X, Ramos-Casals M, Brito-Zerón P, Sjögren Big Data Consortium.
    Clin Exp Rheumatol; 2019 Feb 08; 37 Suppl 118(3):97-106. PubMed ID: 31464664
    [Abstract] [Full Text] [Related]

  • 17. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome.
    Ture HY, Kim NR, Nam EJ.
    Life (Basel); 2023 Sep 29; 13(10):. PubMed ID: 37895373
    [Abstract] [Full Text] [Related]

  • 18. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
    Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K.
    Arthritis Res Ther; 2017 Oct 24; 19(1):237. PubMed ID: 29065905
    [Abstract] [Full Text] [Related]

  • 19. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L, Gandolfo S, Zabotti A, Zandonella Callegher S, Fabro C, De Vita S.
    Front Immunol; 2019 Oct 24; 10():1527. PubMed ID: 31354708
    [Abstract] [Full Text] [Related]

  • 20. Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for Sjögren's syndrome: Findings from the NIH cohort.
    Billings M, Amin Hadavand M, Alevizos I.
    Oral Dis; 2018 Mar 24; 24(1-2):184-190. PubMed ID: 29480635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.